Vanda Pharmaceuticals(VNDA) - 2024 Q2 - Quarterly Results

Exhibit 99.1 Vanda Pharmaceuticals Reports Second Quarter 2024 Financial Results ® ® • Revenues for Q2 2024 were $50.5 million, an increase of 6% compared to Q1 2024 and an increase of 10% compared to Q2 2023 • Financial Guidance reinstated for Full Year 2024 • Fanapt approved for the acute treatment of bipolar I disorder; commercial launch initiated in Q3 2024 • PONVORY commercial launch in multiple sclerosis initiated in Q3 2024 • Tradipitant NDA review for gastroparesis ongoing; PDUFA date of September 1 ...